Development and introduction of recombinant factor VIII - a clinician's experience

Haemophilia

Volumn 18, Issue 4, 2012, Pages 483-486

  Lusher, J M ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLEEDING; BLOOD TRANSFUSION; CRYOPRECIPITATION; DISEASE TRANSMISSION; DRUG EFFICACY; FREEZE DRYING; GENE MUTATION; HEMOPHILIA A; HUMAN; NOTE; PRIORITY JOURNAL; SAFETY; X CHROMOSOME;

FACTOR VIII; HEMOPHILIA A; HISTORY, 20TH CENTURY; HUMANS; RECOMBINANT PROTEINS;

EID: 84863229090     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02804.x     Document Type: Note

References (40)

1. Pool JG, Shannon AE. Production of high-potency concentrates of antihemophilic globulin in a closed-bag system. N Engl J Med 1965; 273: 1443-7.
2. Webster WP, Roberts HR, Thelin GM, Wagner RH, Brinkhous KM. Clinical use of a new glycine-precipitated antihemophilic fraction. Am J Med Sci 1965; 250: 643-51.
3. Evatt BL, Gomperts ED, McDougal JS, Ramsey RB. Coincidental appeartance of LAV/HTLV-III antibodies in hemophiliacs and the onset of the AIDS epidemic. N Engl J Med 1985; 312: 483-6.
4. Johnson RE, Lawrence DN, Evatt BL et al. Acquired immunodeficiency syndrome among patients attending hemophilia treatment centers and mortality experience of hemophiliacs in the United States. Am J Epidemiol 1985; 121: 797-810.
5. Pierce GF, Lusher JM, Brownstein AP, Goldsmith JC, Kessler CM. The use of purified clotting factor concentrates in hemophilia. Influence of viral safety, cost and supply on therapy. JAMA 1989; 261: 3434-8.
6. National Hemophilia Foundation Medical and Scientific Advisory Council (MASAC)Recommendation concerning the treatment of hemophilia and related bleeding disorders. Medical Advisory No. 301. New York: National Hemophilia Foundation, 1997.
7. ®-P: history and clinical performance. Eur J Haematol 2008; 80(Suppl. 70): 3-35.
8. Lusher JM, Salzman PM, The Monoclate Study Group. Viral safety and inhibitor development associated with factor VIII C ultra-purified from plasma in hemophiliacs previously unexposed to factor VIII C concentrates. Semin in Hematol 1990; 27(Suppl. 2): 1-7.
9. Lusher JM. Viral safety and inhibitor development associated with monoclonal antibody-purified FVIII C. Ann Hematol 1991; 63: 138-41.
10. Brettler DB, Forsberg AD, Levine PH. Factor VIII:C concentrate purified from plasma using monoclonal antibodies: human studies. Blood 1989; 73: 59-63.
11. Piszkiewicz D, Sun CS, Tondreau SC. Inactivation and removal of human immunodeficiency virus in monoclonal antibody purified antihemophilic factor (human) (Hemofil M). Thromb Res 1989; 55: 627-34.
12. Gitschier J, Wood WI, Goralka TM et al. Characterization of the human factor VIII gene. Nature 1984; 312: 326-30.
13. Wood WI, Capon DJ, Simonsen CC et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312: 330-7.
14. Vehar GA, Keyt B, Eaton D et al. Structure of human factor VIII. Nature 1984; 312: 337-42.
15. Toole JT, Knopf JL, Wozney JM et al. Molecular cloning of a cDNA encoding human antihemophilic factor. Nature 1984; 312: 342-7.
16. White GC, McMillan CW, Kingdon HS, Shoemaker CB. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia. N Engl J Med 1989; 320: 166-70.
17. White GC, Courter S, Bray GL, Lee M, Gomperts ED. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. Thromb Haemost 1997; 77: 660-7.
18. Schwartz RSS, Abildgaard CF, Aledort LM et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. N Engl J Med 1990; 323: 1800-5.
19. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. N Engl J Med 1993; 328: 453-9.
20. Bray GL, Gomperts ED, Courter S et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994; 83: 2428-35.
21. Gruppo R, Chen H, Schroth P, Bray GL. Safety and immunogenicity of recombinant factor VIII (Recombinate) in previously untreated patients: a 7.3year update. Haemophilia 1998; 4: 228.(Abstract # 291, XXIII Congress of the WFH, The Hague).
22. Lusher JM. Summary of clinical experience with recombinant factor VIII products - Kogenate. Ann Hematol 1994; 68: S3-6.
23. Lusher JM. Recombinant clotting factor concentrates. Bailliere's Clin Haematol 1996; 9: 291-303.
24. Lusher J, Abildgaard C, Arkin S et al. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation. J Thromb Haemost 2004; 2: 574-83.
25. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
26. Addiego JE, Kasper CK, Abildgaard CF et al. Frequency of inhibitor development in haemophiliacs treated with low purity factor VIII. Lancet 1993; 342: 462-4.
27. Lusher JM. Inhibitors in young boys with haemophilia. Bailliere's Clin Haematol 2000; 13: 457-68.
28. White GC, DiMichele D, Mertens K et al. Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendations of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Thromb Haemost 1999; 81: 462.
29. Kreuz W, Gill JC, Rothschild C et al. Full-length sucrose-formulated recombinant factor FVIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost 2005; 93: 457-67.
30. ®FS/Bayer. Int J Hematol 2009; 90: 446-54.
31. Blanchette VS, Shapiro AD, Liesner RJ et al. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008; 6: 1319-26.
32. Musso R, Santagostino E, Faradji A et al. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting. Thromb Haemost 2006; 99: 52-8.
33. Sandberg H, Almstedt A, Braudt J. Structural and funcitonal characteristics of a B-domain deleted recombinant factor VIII molecule, r-VIII SQ. Thromb Haemost 2001; 85: 93-100.
34. Mikaelsson M, Eriksson B, Lind P et al. Manufacturing and characterization of a new B-domain deleted recombinant factor VIII, r-VIII SQ. Thromb Haemost 1993; 69: 1205. Abstract No. 2359.
35. Lusher JM, Lee CA, Kessler CM, Bedrosian CL. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 38-49.
36. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Semin Hematol 2001; 38(Suppl. 4): 44-51.
37. Recht M, Nemes L, Matysiak M et al. Clinical evaluation of moroctogoc alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy and pharmacokinetic equivalence to full-length recombinant FVIII. Haemophilia 2009; 15: 869-80.
38. Scharrer I, Bray GL, Neurtzling O. Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 5: 145-54.
39. Scharrer I, Ehrlich HJ. Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII. Haemophilia 2001; 7: 346-8.
40. Lusher JM. Is the incidence and prevalence of inhibitors greater with recombinant products? No.J Thromb Haemost 2004; 2: 863-5.